174 related articles for article (PubMed ID: 37086273)
1. Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
Zboralski D; Osterkamp F; Christensen E; Bredenbeck A; Schumann A; Hoehne A; Schneider E; Paschke M; Ungewiss J; Haase C; Robillard L; Simmons AD; Harding TC; Nguyen M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2621-2635. PubMed ID: 37086273
[TBL] [Abstract][Full Text] [Related]
2. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
Zboralski D; Hoehne A; Bredenbeck A; Schumann A; Nguyen M; Schneider E; Ungewiss J; Paschke M; Haase C; von Hacht JL; Kwan T; Lin KK; Lenore J; Harding TC; Xiao J; Simmons AD; Mohan AM; Beindorff N; Reineke U; Smerling C; Osterkamp F
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3651-3667. PubMed ID: 35608703
[TBL] [Abstract][Full Text] [Related]
4. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.
Xu M; Chen J; Zhang P; Cai J; Song H; Li Z; Liu Z
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3214-3224. PubMed ID: 37318538
[TBL] [Abstract][Full Text] [Related]
5. Integrin α
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
8. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
9. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW
J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111
[TBL] [Abstract][Full Text] [Related]
11. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
12. The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy.
Zhang Y; Akhil V; Seo HS; Park HR; Kim SH; You SH; Liu Z; Kim SY; Sultonova RD; Min JJ; Hong Y
Theranostics; 2024; 14(3):1195-1211. PubMed ID: 38323311
[TBL] [Abstract][Full Text] [Related]
13. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
Zhao Z; Liu S; Sun R; Zhu W; Zhang Y; Liu T; Li T; Jiang N; Guo H; Yang R
Front Immunol; 2023; 14():1085476. PubMed ID: 36960067
[TBL] [Abstract][Full Text] [Related]
14. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
15. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
16.
Li H; Ye S; Li Li ; Zhong J; Yan Q; Zhong Y; Feng P; Hu K
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2705-2715. PubMed ID: 35290473
[TBL] [Abstract][Full Text] [Related]
17. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors.
Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A
Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491
[No Abstract] [Full Text] [Related]
18. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
19. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
20. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]